Pairing Psilocybin With Transauricular Vagus Nerve Stimulation (ENHANCE)
Randomised, triple-blind Phase I factorial trial (n=108 planned) testing whether adjunctive taVNS enhances the long-term beneficial effects of a single open-label 25 mg psilocybin dose in medically healthy adults with modest reductions in wellbeing.
Details
A factorial, randomized study in healthy volunteers comparing combinations of active or sham transcutaneous auricular vagus nerve stimulation (taVNS) delivered before and after a single open-label 25 mg psilocybin dose to examine whether taVNS enhances retention of insights and long-term beneficial behavioural effects.
Participants receive 2–4 hours of preparatory support, a 6–8 hour psilocybin dosing session, and integration sessions at 1 day and ~1 week post-dosing; taVNS (active or sham) is delivered 20 minutes twice daily for 7 days according to randomisation.